Taisho Signs Agreement With Mochida On Epadel Switch OTC’s Marketing Rights
This article was originally published in PharmAsia News
Executive SummaryJapanese major over-the-counter drug maker Taisho Pharmaceutical signed an agreement with Mochida Pharmaceutical and obtained exclusive marketing rights to hyperlipidemia drug Epadel (ethyl icosapentate) switch OTC products. Mochida is the world's first drug maker to develop high grade ethyl icosapentate as a therapeutic agent to treat symptoms of hyperlipidemia and arteriosclerosis obliterans. Epadel was launched in Japan in 1990 and Mochida is applying for manufacturing and marketing approval for the drug's switch to OTC products. Taisho has a broad sales network and extensive marketing experience in Japan's OTC market. (Click here for more - Japanese language
You may also be interested in...
Cannabidiol (CBD) represents an intriguing opportunity for cosmetics, without the statutory obstacles faced by food and dietary supplement companies. Cosmetics marketers are taking advantage, but the FDA’s recent warning letter blitz is a reminder that CBD-infused beauty products are bound by the same rules that apply to other cosmetics.
Analyzing Quality Data Is Essential. Here’s What One Expert Says Your Firm Should Do To Stay In FDA’s Good Graces
Device makers should make sure they have adequate resources to analyze quality data they take in so they can prevent the recurrence of nonconforming products, processes and procedures. That’s just one nugget of advice from former FDA investigations branch director Ricki Chase, who explains why collecting and properly handling such data is critical to complying with agency expectations in this Medtech Insight Q&A interview.